S Mohana Sundaram

Dr. S Mohana Sundaram

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Life Sciences
Verified
Journal Article
Closed access
S Mohana SundaramS Mohana Sundaram
S Mohana Sundaram
LVLavanya Varier
Lavanya Varier
KFKhan Zahara Fathima
Khan Zahara Fathima
ADArun Dharmarajan
Arun Dharmarajan
SWSudha Warrier
Sudha Warrier

17 February 2023 in Cancers
Verified
Journal Article
Open access
PDF file
LVLavanya Varier
Lavanya Varier
S Mohana SundaramS Mohana Sundaram
S Mohana Sundaram
NGNaisarg Gamit
Naisarg Gamit
SWSudha Warrier
Sudha Warrier
Ovarian cancer is one of the most prevalent gynecological cancers, having a relatively high fatality rate with a low five-year chance of survival when detected in late stages. The early detection, treatment and prevention of metastasis is pertinent and a pressing research priority as many patients are diagnosed only in stage three of ovarian cancer. Despite surgical interventions, targeted immunotherapy and adjuvant chemotherapy, relapses are significantly higher than other cancers, suggesting the dire need to identify the root cause of metastasis and relapse and present more precise therapeutic options. In this review, we first describe types of ovarian cancers, the existing markers and treatment modalities. As ovarian cancer is driven and sustained by an elusive and highly chemoresistant population of cancer stem cells (CSCs), their role and the associated signature markers are exhaustively discussed. Non-invasive diagnostic markers, which can be identified early in the disease using circulating tumor cells (CTCs), are also described. The mechanism of the self-renewal, chemoresistance and metastasis of ovarian CSCs is regulated by the Wnt signaling pathway. Thus, its role in ovarian cancer in promoting stemness and metastasis is delineated. Based on our findings, we propose a novel strategy of Wnt inhibition using a well-known Wnt antagonist, secreted frizzled related protein 4 (sFRP4), wherein short micropeptides derived from the whole protein can be used as powerful inhibitors. The latest approaches to early diagnosis and novel treatment strategies emphasized in this review will help design precision medicine approaches for an effective capture and destruction of highly aggressive ovarian cancer.

1 June 2015 in Tissue Engineering Part A
Verified
Journal Article
Open access
ECElizabeth A. Calle
Elizabeth A. Calle
JMJulio J. Mendez
Julio J. Mendez
MGMahboobe Ghaedi
Mahboobe Ghaedi
KLKatherine L. Leiby
Katherine L. Leiby
PBPeter F. Bove
Peter F. Bove
LNLaura E. Niklason
Laura E. Niklason
Type II cells are the defenders of the alveolus. They produce surfactant to prevent alveolar collapse, they actively transport water to prevent filling of the air sacs that would otherwise prevent gas exchange, and they differentiate to type I epithelial cells. They are an indispensable component of functional lung tissue. To understand the functionality of type II cells in isolation, we sought to track their fate in decellularized matrices and to assess their ability to contribute to barrier function by differentiation to type I alveolar epithelial cells. Rat type II cells were isolated from neonatal rat lungs by labeling with the RTII-70 surface marker and separation using a magnetic column. This produced a population of ∼50% RTII-70-positive cells accompanied by few type I epithelial cells or α-actin-positive mesenchymal cells. This population was seeded into decellularized rat lung matrices and cultured for 1 or 7 days. Culture in Dulbecco's modified Eagle's medium +10% fetal bovine serum (FBS) resulted in reduced expression of epithelial markers and increased expression of mesenchymal markers. By 7 days, no epithelial markers were visible by immunostaining; nearly all cells were α-actin positive. Gene expression for the mesenchymal markers, α-actin, vimentin, and TGF-βR, was significantly upregulated on day 1 (p=0.0005, 0.0005, and 2.342E-5, respectively). Transcript levels of α-actin and TGF-βR remained high at 7 days (p=1.364E-10 and 0.0002). Interestingly, human type II cells cultured under the same conditions showed a similar trend in the loss of epithelial markers, but did not display high expression of mesenchymal markers. Rat cells additionally showed the ability to produce and degrade the basement membrane and extracellular matrix components, such as fibronectin, collagen IV, and collagen I. Quantitative real-time reverse transcription polymerase chain reaction (RT-PCR) showed significant increases in expression of the fibronectin and matrix metalloprotease-2 (MMP-2) genes after 1 day in culture (p=0.0135 and 0.0128, respectively) and elevated collagen I expression at 7 days (p=0.0016). These data suggest that the original type II-enriched population underwent a transition to increased expression of mesenchymal markers, perhaps as part of a survival or wound-healing program. These results suggest that additional medium components and/or the application of physiologically appropriate stimuli such as ventilation may be required to promote lung-specific epithelial phenotypes.

1 December 2021 in Experimental Cell Research
Verified
Journal Article
Closed access
IYIshmat Ara Yasmin
Ishmat Ara Yasmin
S Mohana SundaramS Mohana Sundaram
S Mohana Sundaram
ABAnasuya Banerjee
Anasuya Banerjee
LVLavanya Varier
Lavanya Varier
Arun DharmarajanArun Dharmarajan
Arun Dharmarajan
SWSudha Warrier
Sudha Warrier

11 August 2023 in Drug Development Research
Verified
Journal Article
Open access
NGNaisarg Gamit
Naisarg Gamit
MPManasi Patil
Manasi Patil
SSSoumya B Sundrappa
Soumya B Sundrappa
S Mohana SundaramS Mohana Sundaram
S Mohana Sundaram
Gautam SethiGautam Sethi
Gautam Sethi
SWSudha Warrier
Sudha Warrier
A reliable and efficient in vitro model is needed to screen drugs for Alzheimer's disease (AD), as many drugs are currently in the developmental stage. To address this, we developed an in vitro model using amniotic membrane‐derived mesenchymal stem cells (AM‐MSCs) to screen novel drugs for AD. We differentiated AM‐MSCs into neurons and degenerated them using beta amyloid1‐42 (Aß). We then tested AD drugs, which are commercially available such as donepezil, rivastigmine, memantine, citicoline, and two novel drugs, that is, probucol, an anti‐hyperlipidaemic drug, and NMJ‐2, a cinnamic acid analogue for their potential to protect the cells against neurodegeneration. We used gene expression and immunofluorescence staining to assess the neuroprotective ability of these drugs. We also measured the ability of these drugs to reduce lactate dehydrogenase, reactive oxygen species, and nitric oxide levels, as well as their ability to stabilize the mitochondrial membrane potential and increase acetylcholine (ACh) levels. The AD drugs and novel drugs reduced cytotoxicity and oxidative stress, stabilized mitochondrial membrane potential, and restored ACh levels. Furthermore, they reduced BACE1 expression, with a concomitant increase in the expression of cholinergic markers. This AM‐MSCs‐based AD‐like model has immense potential to be an accurate human model and an alternative to animal models for testing a large number of lead compounds in a short time. Our results also suggest that the novel drugs probucol and NMJ‐2 may protect against Aß‐induced neurodegeneration.

6 December 2021 in Placenta
Verified
Journal Article
Closed access
SWSudha Warrier
Sudha Warrier
S Mohana SundaramS Mohana Sundaram
S Mohana Sundaram
LVLavanya Varier
Lavanya Varier
ABAnanthakrishnan Balasubramanian
Ananthakrishnan Balasubramanian